Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabergoline + hydroxyethyl starch
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy approach using cabergoline (a dopamine receptor agonist) and hydroxyethyl starch (a plasma volume expander) for the prevention of ovarian hyperstimulation syndrome (OHSS) in women undergoing in vitro fertilization. Cabergoline works by inhibiting prolactin secretion and reducing vascular permeability, while hydroxyethyl starch is administered as an intravenous solution to maintain blood volume.
02
Targets
5-HT2 (5-HT2 receptor family)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)ADRA1 (Alpha-1 adrenergic receptor family)
Beyond the preview
Go deeper on cabergoline + hydroxyethyl starch.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabergoline + hydroxyethyl starch.